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ABSTRACT
With the current focus on the role of n-3 PUFAs as beneficial dietary interventions in the

fields of cardiovascular disease and cancer, there has been a vastly increased awareness

and focus on the mechanism of action for these essential fatty acids.

Many of the effects of PUFAs are mediated via changes in prostaglandin (PG)

levels. One primary substrate for PGs is arachidonic acid (AA) (20:4 n-6), which results

in the production of 2-series PGs. Increased concentrations of AA have been shown to

increase levels of PGE2 in vitro and in vivo. The omega-3 fatty acid EPA (20:5 n-3) is of

particular interest due to its incorporation into cell membrane phospholipids in

competition with AA. EPA can also serve as a substrate for prostaglandin production

when present in tissue and results in the production of 3-series PGs, which do not appear

to produce the same effects as 2-series PGs, although data is extremely limited. The

secretion of prostaglandins (PGs), and specifically PGE 2 has been demonstrated in human

and rodent adipocytes, and the presence of PGE2 receptors in these tissues has also been

demonstrated. PGE 2 can act in an autocrine/paracrine fashion in adipocytes to decrease
lipolysis via G-protein coupled receptors. Preliminary data from our lab on Ape Mini+

mice showed that cyclooxygenase (COX) inhibition significantly reduced the activity of
fatty acid synthase (FAS) in adipose tissue, and PGE2 receptor agonists partially but

significantly reversed this effect.

Our overall objective was to determine whether treatment with EPA or selective

COX-2 inhibitors would lead to a reduction in measured PGE 2 that would in tum regulate
markers of lipogenesis. We hypothesized that increased levels of EPA would

competitively reduce tissue AA levels, and consequently PGE2 production, leading to
decreased activity of markers specific to adipogenesis, specifically the FAS enzyme.

Selective COX-2 inhibition was expected to produce similar effects via inhibition of

COX metabolism of AA to PGs. Studies were conducted on 3T3-Ll adipocytes. Dose

response studies demonstrated a clear relationship between increasing doses of EPA or

AA and measured PGE2/PGE3 levels. Manipulation of PGE2 levels via addition of EPA
to culture media led to significant changes in measured PGE2 levels versus AA, but did

not result in a significant decrease in FAS enzyme activity. Addition of celecoxib, a
lV

selective COX-2 inhibitor (CI), to culture media resulted in a significant decrease in
PGE2 levels and FAS activity. Addition of exogenous PGE2 to CI treatment did not
reverse the decreased FAS enzyme activity. These results indicate that addition of EPA
can displace AA in cell membrane phospholipids and reduce PGE2 production, but does
not impact FAS activity. Suppression of PGE2 by selective COX-2 inhibition does lead
to decreased FAS activity, which is not reversed by exogenous PGE2 addition.
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CHAPTER I
INTRODUCTION
Obesity rates in the United States continue to increase at an alarming rate despite

increasing attention from medical professionals, government officials and the media

regarding the seriousness of this problem. The most current statistics indicate that 64.5%

of Americans are overweight (BMI � 25), and that 30.5% of those who are overweight

can be classified as obese (BMI � 30) [l ]. The direct impact of this problem is related to

the increased risk of disease and mortality since obesity is a known risk factor for heart
disease, hypertension, diabetes and some cancers [2]. The indirect implications of this
epidemic of excess weight have manifested as a crippling financial burden to our

healthcare system. For example, obesity-attributable medical expenditures were

estimated to be $75 billion in 2003 dollars with approximately one-half of these expenses

paid by Medicare and Medicaid [3].

Recent work in the fields of cardiovascular disease and cancer has demonstrated a

possible role for omega-3 fatty acids as beneficial dietary interventions, and as a result

has greatly increased scientific and public awareness of these essential polyunsaturated

fatty acids (PUFAs) [4-7]. One of the cornerstones for decreasing adiposity has been the

recommendation to decrease caloric intake by lowering fat intake due to its high calorie
density [2, 8]. This emphasis on low fat diets, although sound from a calorie intake

standpoint, may have led to an inadvertent decrease in the consumption of essential fats,
such as omega-3 fatty acids, in the typical American diet.

Many of the effects of these omega-3 PUFAs are mediated via changes in

prostaglandin (PG) levels [4, 9-11]. PGs are chemical messengers derived from PUF As

selectively cleaved from the sn-2 position of cell membrane phospholipids [9] (see fig. 4
on page 12). Prostaglandin E2 (PGE2) is of particular interest in the area of energy

metabolism and obesity, since it has been shown to decrease lipolysis, or triacylglycerol

breakdown [12, 13], and potentially increase the activity of the fatty acid synthase (FAS)
enzyme resulting in increased endogenous fatty acid production. One primary substrate
for PGs is arachidonic acid (AA) (20:4 n-6), which results in the production of 2-series
1

PGs [4] such as PGE2. Increased concentrations of AA have been shown to increase
levels of PGE2 in vitro and in vivo [5, 14].
The omega-3 fatty acid eicosapentaenoic acid (EPA) (20:5 n-3) is also
incorporated into cell membrane phospholipids in direct competition with AA [ 15]. EPA
can serve as a substrate for prostaglandin production when present in tissue and results in
the production of 3-series PGs, which appear to produce weaker effects when compared
to the 2-series PGs, although data remain extremely limited [16].
In addition to competitive inhibition with EPA, PG formation can also be
inhibited via inhibition of the COX pathway [17-20]. The use of both non-selective COX
inhibitors and selective COX-2 inhibitors has been shown to decrease PGE2 secretion in
adipocytes [12, 21-23]. This pharmacological intervention represents a means to
precisely target PGE2 metabolism to assist in understanding the role it plays in adipocyte
metabolism.
Available data suggests the possibility of impacting aspects of lipid metabolism
by manipulating PGE2 levels. Accordingly, the goal of this research is to utilize EPA or
celecoxib (selective COX-2 inhibitor) to inhibit AA metabolism to PGE2 and determine
the effect on markers of adipocyte lipogenesis.
More specifically our aims are:
1. To determine if the endogenous production of PGE2 can be decreased by the
addition of exogenous EPA or selective COX-2 inhibitor to cultured adipocytes.
2. To determine if a decrease in endogenous PGE2 production by adipocytes results
in a decrease in markers of lipogenesis, specifically the activity of the FAS
enzyme.
Findings from this project may provide a foundation for further research that will help
clarify: 1) The role for interventions aimed at decreasing PGE2 synthesis in reducing
lipogenic activity in adipocytes and 2) The public health recommendations for omega-3
fatty acids, and specifically for EPA, in the diet of Americans, including the potential
roles of EPA in weight management.
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CHAPTER II
LITERATURE REVIEW
I.

OBESITY
A. Incidence and Implications

Body mass index (BMI) is the most consistently used measure to indicate excess

weight, and is defined as weight in kilograms divided by height in meters squared

{ weight in kg / (height in meters)2 } [2]. BMI is now universally used since the World

Health Organization (WHO) recommendations and National Institutes of Health (NIH)

report in 1997 and 1999, respectively [24, 25]. Although less accurate in certain

populations, such as athletes, children and the elderly [26], BMI correlates well with both

morbidity and mortality for most adults and provides a convenient, non-invasive and

affordable tool in the clinical setting to classify overweight and obesity (Table 1) [2].

In recent years the incidence of overweight and obesity has received tremendous

attention as these conditions have reached epidemic proportions in the United States as

well as other countries. This is evidenced by a large volume of resources being invested

into understanding the processes involved as well as the interventions that can most

effectively halt and/or reverse these conditions. The most current statistics indicate that
64.5% of Americans are overweight (BMI � 25), and that 30.5% of those who are
overweight can be classified as obese (BMI � 30) [1].

With increased weight comes increased risk of death and disease. For the average

middle-aged adult, an excess of 10-20 pounds can increase the risk of mortality [27].

Younger adults are more impacted by excess weight than older adults, as indicated by

data showing greater years of life lost to obesity than older adults [28]. Being overweight
or obese is also implicated as a risk factor in several disease states, including diabetes,

heart disease, hypertension, some cancers, and stroke [26], all of which contribute to the

increased risk of death (Table 2) [29]. Recently it has been reported that approximately
400,000 deaths per year can be attributed to obesity related causes [30]. This makes

obesity second only to smoking as a cause of preventable death in the U.S.
3

Table 1. Classification of Overweight and Obesity by BMI
2

Classification

Obesity Class

BMI (kg/m )

Underweight

---

<18.5

Overweight

---

Normal

---

Obesity

I

30.0-34.9

III

�40

Extreme Obesity

II

18.5-24.9

25.0-29.9

35.0-39.9

National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and
Treatment of Overweight and Obesity in Adults: the evidence report

Table 2. Rank of Selected Conditions in 2001 Leading Causes of U.S. Deaths
Rank

Condition

Number of Deaths

Percent of Total

1

Heart Disease

700,142

29

6

Diabetes

71,372

3.0

2

3

14

Cancer
Stroke

553,768

163,538

Essential Hypertension 19,250

22.9
6.8

0.8

Anderson, R.N., A.M. Minino, L.A. Fingerhut, M. Warner, and M.A. Heinen. Deaths: injuries, 2001. Natl
Vital Stat Rep., 2004. 52(21)
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Research has shown that obese individuals have 36% higher average medical
expenditures when compared to normal weight individuals [31]. Estimates of U.S.
obesity-attributable medical expenses were $75 billion for 2003, with approximately one
half of these financed by Medicare and Medicaid [3]. As the number of overweight and
obese individuals continues to climb, so will the burden placed on financial and medical
resources of the U.S.
B. Causative Factors

The etiology of obesity is complex and multi-factorial including genetic,
metabolic, environmental and behavioral factors [32]. Since genetic factors are
predetermined, the primary factors that are controllable, and thus the target for
intervention, are environmental and behavioral factors. Lifestyle modifications, and
more specifically increasing activity while maintaining or decreasing caloric intake, are
the cornerstones of the current effort to reduce the incidence of overweight and obesity
[2, 26]. In 1998 it was estimated that 29% of adult Americans were sedentary, 44%
participated in some physical activity but still did not meet the recommended 30 minutes
of activity on most days, and only 27% of adults actually achieved the recommended
amount of activity [33]. In addition to the limited activity prevalent in our society,
caloric intake has also increased. During the time period from 1971-2000, average
energy intake for men increased from 2,450 calories to 2,618 calories, and energy intake
for women increased from 1,542 calories to 1,877 calories, with more recent data
indicating that this trend has continued [34]. These specific lifestyle factors, coupled
with other environmental influences on the genetics of obesity, have been the driving
force behind the epidemic that now faces our nation [35].
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II.

POLYUNSATURATED FATTY ACIDS
A. Description and Metabolism

Fatty acids (FAs) are molecules that are composed of hydrocarbons with a methyl

end (C-CH3) and a carboxylic acid end (C-COOH). One means of classification of these
fatty acids is relative to the number of double bonds. Polyunsaturated fatty acids

(PUFAs) are FAs that contain two or more double bonds. From a nutrition standpoint,

there are two sub-classes of PUFAs that are considered essential due to the proximity of

the double bond to the methyl end, also called the omega end. Omega-3 fatty acids have
the first double bond 3 carbons away from the omega end, thus the designation omega-3
and often written n-3. Omega-6 fatty acids have the first double bond 6 carbons away
from the omega end and are thus termed omega-6 (n-6) (Fig. 1).

These two classes ofFAs are essential for humans and must be obtained from the

diet due to the lack of the enzymes necessary to add these double bonds to fatty acids

without them. The two primary essential FAs in the American diet include the n-6

linoleic acid (LA) and the n-3 alpha-linolenic acid (ALA) since they can be metabolized
into the longer bioactive arachidonic acid (AA), eicosapentaenoic acid (EPA), and

docosahexaenoic acid (DHA). In the United States, PUFAs contribute approximately 7%
of total energy intake and 19-22% of the energy intake from fat. LA, the primary n-6

PUFA consumed, compromises 84-89% of the total energy from PUFAs (36]. ALA is

the primary n-3 fatty acid consumed, and makes up approximately 0.7% of total energy
from PUFAs [36].

LA is converted to y-linolenic acid (GLA, 18:3 n-6) via the Li-6 desaturase

enzyme, and subsequently converted to AA through the intermediate dihomo- y-linolenic

acid (DGLA, 20:3 n-6) via successive steps involving the elongase and Li-5 desaturase

enzymes. Following the same pathway, ALA is converted to EPA via the intermediates
stearidonic acid (18:4 n-3) and eicosatetraenoic acid (20:4 n-3). This pathway then

continues through further elongation, desaturation, and peroxisomal P-oxidation to
produce docosahexaenoic acid (22:6 n-3) as a final end product (Fig. 2).
6

COOH
H3C
Omega end

LA (18:2, n-6)

Omega-6

COOH
ALA (18:3, n-3)

Omega-3

Figure 1. Linoleic Acid and Alpha-Linolenic Acid

n-3 Family

n-6 Family

a-Linolenic acid ( 1 8 :3 n-3)

Linoleic acid ( 1 8 :2 n-6)

't
y-Linolenic acid (1 8:3 n-6)
't

A-6 Desaturase

Stearidonic acid ( 1 8 :4 n-3)
Elongase
Eicosatetraenoic acid (20:4 n-3)

Dihomo y-Linolenic acid (20:3 n-6)
Ll-5 Desaturase

Eicosapentaenoic acid (20 :5 n-3)

Arachidonic acid (20:4 n-6)

Elongase
Elongase
�-6 Desaturase
J3-oxidation
Docosahexaenoic acid (22:6 n-3)
Figure 2. Arachidonic Acid and Eicosapentaenoic Acid Synthesis
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The rate-limiting enzyme for this pathway is 6-6 desaturase [37], and this aspect is

critical from a nutritional standpoint. Since LA and ALA compete for this enzyme, and

since the majority of the PUFA intake in the U.S. is made up of the n-6 fatty acid LA, the

fatty acids produced in this pathway are skewed towards members of the n-6 family, with
AA the predominate end product [38, 39]. Increasing intake of the n-3 fatty acid ALA is

often recommended to competitively inhibit the production of AA, and has been shown to
be moderately successful in some studies [15, 40, 41], although there is some evidence

that even when consumed in a 1: 1 ratio the tissue levels of n-6 fatty acids may exceed the
tissue levels of n-3 fatty acids [42]. A second, and possibly more effective, means of

reducing tissue levels of AA is to consume the preformed n-3 fatty acid EPA, which has
been shown to compete with AA for incorporation into cell membrane phospholipids

leading to increased levels of EPA [43-45]. The effectiveness of this strategy may

depend on the foods from animal sources that make up an individual's diet, as studies in

mice have shown that when preformed AA and EPA were fed in equal amounts, tissue
phospholipids contained higher concentrations of AA [14].
B. Role In Weight Loss

Replacement of AA with fatty acids of the n-3 family in tissue phospholipids, and

specifically EPA, is one of the mechanisms on which the recommendations for increasing

consumption of these PUFAs are based [6]. AA serves as a substrate for the action of

several enzymes that produce eicosanoids, specifically PGs, thromboxanes (TXs),

hydroxyeicosatetraenoic acids (HETEs), and leukotrienes (LTs) [4]. These eicosanoids

serve as chemical messengers in intracellular and intercellular signaling, and many of the

eicosanoids produced from AA have been implicated in inflammation and diseases states

such as cancer [5, 1 0, 43, 46-48]. EPA can be metabolized by the same enzymes as AA
producing similar but distinct eicosanoids which appear to have weaker action with

regards to inflammation [16, 43, 49, 50]. Although the impact on inflammation is a

major focus for the role of n-3 fatty acids, it is not the only means by which these PUFAs

may impact disease conditions.

8

There is an increasing body of evidence that PUFAs themselves may impact
disease conditions, and specifically the conditions of overweight and obesity. This
impact is most likely a combination of the physiological, biochemical, and genetic effects
of these fatty acids. From a physiological standpoint, dietary n-3 fatty acids increase cell
membrane permeability [51], possibly influencing the selectivity and rate of substances
crossing the membrane. In addition, PUFAs can reduce the triglyceride accumulation in
skeletal muscle [52], and may impact accumulation in other tissues as well, which is
associated with improvements in insulin sensitivity [52, 53].
From a biochemical standpoint, dietary PUFAs impact eicosanoid levels as
discussed above with a wide range of consequences. In addition, PUFAs modulate the
activity and gene expression of several proteins in either an eicosanoid-dependent or
independent manner [54]. For example, PUFAs appear to impact leptin levels in a
manner that may be independent of eicosanoid secretion [55-57]. Leptin is a hormone
secreted by adipocytes that impacts food intake, energy expenditure, and energy balance
while also potentially impacting insulin sensitivity and diabetes. Increased levels of
circulating leptin are associated with decreased food intake, increased thermogenesis, and
decreased adipose tissue mass [58]. Growing evidence suggests that leptin may be
implicated in a variety of pathophysiologies associated with obesity, making it a focus in
the battle against this epidemic. Rats fed diets high in n-6 or n-3 fatty acids had
significantly higher leptin levels versus animals fed beef tallow, independent of fat mass
[55]. In vitro, EPA was shown to significantly increase leptin secretion and mRNA
expression in 3T3-Ll adipocytes [56]. Studies in rat and obese human adipose tissue
explants showed that exposure to the AA metabolite PGE2 from exogenous sources
increased leptin levels [ 1 2, 59]. In contrast, AA was shown to decrease leptin secretion
and mRNA expression in isolated rat adipocytes through a prostaglandin-independent
mechanism [57]. Given this wide range of contrasting effects on leptin, the exact role
and mechanism of PUFA action remains to be clarified.
The most powerful and well-studied role for PUF As in the battle against excess
weight is their impact on gene expression. Peroxisome proliferator-activated receptors
(PPARs) and sterol regulatory element binding proteins (SREBPs) have emerged as the
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key targets that mediate PUFA effects. Both have affinity for one or more PUFAs, and

impact genes involved in lipogenesis or lipolysis.

PPARs are transcription factors belonging to the superfamily of nuclear receptors

and exist in three isoforms (a, o, y). They recognize and bind DNA response elements as
heterodimers with nuclear retinoic acid receptors (RXRs). Activation of PPARs impacts

several genes related to adipocyte development and metabolism [60]. PPAR- a is highly
expressed in hepatocytes, cardiomyocytes, skeletal muscle, and enterocytes, and is the

key player from a weight loss perspective as this isoform primarily promotes lipid

oxidation [�1]. PUFAs have been shown to act as ligands for all three isoforms, with

the affinity for PPAR-a being the greatest [62-64]. In the liver, activation of PPAR-a

induces the expression of transport proteins and enzymes involved in lipid oxidation and
thermogenesis including camitine palmitoyltransferase, peroxisomal acyl-CoA oxidase

and uncoupling protein-3 [65-67]. The net result of these changes is to increase the use

of fatty acids as fuel in mitochondria and peroxisomes and improve glycemic control.

This was demonstrated in PPAR-a knockout mice, which developed characteristics of

adult-onset diabetes such as fatty livers, elevated blood triglycerides, and hyperglycemia
during periods of food deprivation [68]. Less is known at this time regarding PPAR-o,

but some evidence indicates that it may function in a manner similar to PPAR-a [69].
SREBPs are a family of membrane-bound transcription factors that regulate

cholesterol and fatty acid homeostasis, with three isoforms ( l a, l e, 2) identified as well.

PUFAs have been shown to suppress expression of SREBPs (70-72]. SREBP-2 appears
to be involved primarily in cholesterol metabolism with only minor involvement in fatty
acid metabolism [73]. The SREBP-1 isoforms (a, c) are derived from the same gene,

which undergoes alternative splicing to produce the isoforms [74]. The l a isoform is a

much more potent activator of transcription than the l e isoform [75], but the l e form

predominates in liver and adipocytes, although both forms are present (76]. Both

isoforms have demonstrated a role in increasing lipogenic genes in liver and adipose

tissue such as acetyl-CoA-carboxylase (ACC), FAS, and L-pyruvate kinase [71, 75, 77].

They have also been implicated in adipocyte hypertrophy [77]. Increased dietary intake

of PUFAs would therefore lead to increasing expression of genes associated with
10

lipolysis and decreasing expression of genes associated with lipogenesis and a net benefit
of decreased adiposity (Fig. 3). It is still uncertain whether SREBPs and PPARs work
through the same pathway or distinct pathways, with both possibilities still under
investigation.

III.

ARACHIDONIC ACID METABOLISM
A. The Arachidonic Acid Cascade

Arachidonic acid obtained from diet or synthesized from LA is incorporated into
cell membrane phospholipids. AA can be subsequently cleaved from these phospholipids
by the action of various phospholipases, primarily cytosolic phospholipase A2 (cPLA2)
(fig. 4). This occurs when cPLA2 binds to the membrane phospholipid and cleaves the
ester bond linking AA to the glycerol backbone.
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Figure 3. Impact of PUFAs On Gene Expression
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Figure 4. Metabolism of Arachidonic Acid

This initial step is also the rate-limiting step in the metabolism of AA. Liberated AA can

then serves as a substrate for cyclooxygenase (COX) resulting in the production of

prostaglandins of the 2 series [ 1 O].
B. Cyclooxygenase

COX (also called prostaglandin synthase) catalyzes the initial step in the

formation of prostaglandins from the AA precursor via two distinct, sequential

biochemical reactions [78]. The initial step converts AA via cyclooxygenase activity to

the unstable PGG2 , a peroxide intermediate. PGG2 then migrates to the peroxidase active

site where it is further metabolized to PGH2 , which is the parent compound for the

production of PGs and TXs (Fig. 4). COX exists in two isoforms, designated COX-1 and
COX-2. COX- 1 is found in most tissues and is constitutively expressed. It is considered

a housekeeping enzyme with a role in maintaining tissue integrity. This function is of

particular importance in the gastrointestinal (GI) tract, and is largely responsible for the

increased incidence of ulcers and other GI complaints associated with the use of non

specific COX inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDs) [79].
COX-2 is considered an inducible enzyme and is stimulated by growth factors,

inflammatory cytokines, and tumor promoters [ 1 7] , although it is found normally in
12

tissues such as the kidneys [80]. COX-2 is highly homologous to COX-1, with 61% of

the amino acids identical and 84% similar. The relevant difference between the isoforms

is a slightly larger active site that forms a pocket on the COX-2 enzyme [79]. This has
been the key to the development of the class of specific COX-2 inhibitors such as

rofecoxib, celecoxib, and NS 398 [79].

The presence of COX has been demonstrated in preadipocytes and adipocytes [81,

82]. RT-PCR analysis of mRNA in Obl 771 preadipose cells and mature adipocytes

demonstrated that both COX isoforms were present in these cells, with COX-1 present in

much higher quantities. The levels of both forms decreased markedly during the

differentiation process, with COX-1 decreasing approximately 98%, resulting in lower
levels in adipocytes when compared to preadipocytes [21, 82]. The development of

COX-1 and -2 knockout mice has brought to light a dynamic relationship between these

two enzymes. Compared to wild-type mice, the knockout mice expressed the remaining
functional COX gene at higher levels and both knockout models expressed 6-8 fold

higher levels of basal PGE2 versus the control mice [83]. In addition, evidence from

COX knockout mice indicates that COX-2, when expressed, may be the primary enzyme

involved in PGE2 production in many tissues [22, 83].
C. The Role of EPA

The role of EPA in AA metabolism is one of direct competition. Consumption of

preformed EPA bypasses the biosynthetic pathway, allowing increased concentrations to

be available for incorporation into cell membrane phospholipids. The similarity in

structure of these two fatty acids (Fig. 5) allows EPA to readily substitute for AA in the
sn-2 position of triacylglycerols that constitute the cell membrane. Numerous studies
have demonstrated that feeding preformed EPA results in higher levels in plasma and

tissue phospholipids, with a concomitant decrease in levels of AA [5, 15, 84, 85]. Once

incorporated into tissue phospholipids, EPA appears to be mobilized preferentially [8688], and then competes with AA as a substrate for the COX enzymes. EPA is a poor

substrate for both COX enzymes compared to AA [89], but is more efficiently
13
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Figure 5. Structural Similarities of AA and EPA

metabolized by COX-2 [90]. Despite being a poor substrate, much evidence exists that

the availability of EPA leads to decreased production of metabolites of AA [5, 16, 91, 92]

via displacement of AA and also via inhibition of PGE synthase [93]. Due to its 3

double bonds, EPA is converted into 3-series PGs by the action of the COX enzymes.

Data are still limited on the impact of these compounds, but they have shown weaker or

antithetic effects on measures of inflammation when compared to PGE2 [ 16]. One

possible impediment to this role of EPA is the consumption of preformed AA in the diet.

Consumption of preformed AA, even in the presence of equal amounts of EPA, may lead

to increased amounts of AA in tissue phospholipids [14, 94]. This may be problematic in

developed countries such as the U.S. where consumption of meat and animal products is

high, leading to consumption of relevant quantities of AA [95, 96].
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D. PGE 2 Production and Signaling

One of the most thoroughly researched metabolites of AA is PGE2 • It is a potent

mediator of inflammation, produces local pain hypersensitivity, plays a role in fever and
ovulation, and is associated with tumor promotion/survival and osteoporosis as well as

many other normal and abnormal processes [18, 97, 98]. PGE2 is formed as a result of

PGE synthase (PGES) action on PGH2 (see Fig. 4 on page 12). Two isoforms of PGES

exist: cytosolic and membrane-associated. The cytosolic form is expressed in most cells
and tissues and is predominantly coupled to COX-1. The membrane-associated form

appears to be inducible and is preferentially linked to COX-2 [98]. Once formed, PGE2
then acts in an autocrine or paracrine fashion via one of four receptor (EP) subtypes
designated EP 1 through EP4 (Table 3). The discovery and cloning of these receptor

subtypes provided an explanation for the discordant effects of PGE2 , such as smooth

muscle relaxation in some tissues and potent constriction in others [99, 100]. The EP 1

receptor is highly expressed in kidney, gastric mucosa and adrenal tissue, and activation
results in signaling via inositol triphosphate (IP3) generation and increased levels of

intracellular calcium [101, 102]. Acting through the same signaling mechanism,

activation of EP2 or EP4 results in increased levels of cAMP via stimulatory G-protein

coupled receptors. Tissues high in EP2 receptors include the uterus, lung and spleen.

Tissues high in EP4 receptors include the thymus, lung, spleen, adrenal, and kidney [101105]. Activation of EP3 results in inhibition of cAMP production via the inhibitory G

protein coupled receptors, with this receptor highly expressed in kidney, uterus, adrenal,
and stomach tissue [ 102, 106]. The complex interplay of the COX enzymes, three sub

types of PGE, and four sub-types of its receptor have made teasing out the function of
each individual protein or compound most difficult. The dynamic and compensatory

nature of the enzymes, fatty acids, and their metabolites means that isolating one to study

its function and mechanisms may cause abnormal alterations of others leading to
disruption of normal physiology.
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IV.

ADIPOCYTES AND PROSTAGLANDINS
A. Functions of Adipose Tissue

Adipose tissue was traditionally considered a passive tissue whose main role was

energy storage in the form of triglycerides. It is now well established that contrary to this

belief, adipose tissue is in fact a secretory tissue with the potential to impact multiple
tissues and pathways. Serving in an endocrine and autocrine/paracrine role, adipose

tissue secretes compounds such as leptin, angiotensinogen, adiponectin, PGs such as

PGE2 and PGI2 , cytokines such as tumor necrosis factor-a (TNF-a) and interleukin-6
(IL-6), and acylation stimulating protein (ASP). These compounds act upon the

secreting or neighboring cells and/or distant tissues to impact functions such as appetite
and energy balance, immune function, insulin sensitivity and cardiovascular function

[107-114]. Clarification and further understanding of the functions of these bioactive

compounds, as well as the implications of adipocyte hypertrophy and hyperplasia on their
secretion, is vital to understanding the etiology of obesity and its prevention/treatment.
B. 3T3-Ll Cells

The 3T3-Ll cell line is clonally isolated from Swiss 3T3 cells originally derived

form 17-19 day old mouse embryos [115], and is one of the most commonly used cell

lines to study adipocyte biology and function. These cells are fibroblasts or

preadipocytes that are committed to adipocyte lineage. When grown in culture to

confluence, they can be differentiated into mature adipocytes by supplementing culture
media with dexamethasone (Dex) and methylisobutylxanthine (Mix) with or without

insulin [116]. The differentiation process results in the cell morphology changing to a

spherical shape, accumulation of lipid droplets, and other genetic and biochemical

changes associated with the development of the mature adipocyte [115]. Addition of

insulin to the differentiation cocktail serves to accelerate lipid accumulation and results in
larger adipocytes. During and after differentiation, activities of enzymes involved in
triglyceride synthesis are upregulated and the cells become responsive to insulin and
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other hormones, making them excellent models for the study of mammalian adipogenesis
[116-118] . In addition, biochemical and genetic conditions in the cell can be compared

pre-and post-differentiation to help understand the process itself. This quality makes

3T3-Ll adipocytes an ideal choice for the study of adipocyte development and its role in
obesity.

C. PGE 2 and EP Receptors

Numerous studies have demonstrated that adipose tissue and adipocytes in culture

have the capacity to secrete PGE2 under basal conditions and when stimulated by

compounds such as catecholamines, theophylline, and the calcium ionophore A23187

[16, 81, 113, 119]. There was some controversy, however, as to whether prostaglandins

produced from adipose tissue explants were produced by the adipocytes or were in fact

produced by blood vessels and other non-adipose cells found within adipose tissue [120].
Recent work in human adipose tissue explants has demonstrated that human adipocytes

do secrete PGE2 [23, 81] . Adipocytes digested and maintained in culture secreted levels

approximately 4% of tissue explants, while cultured adipocytes secreted levels

approximately 38% that of tissue explants when both were exposed to endogenous AA
[81]. In cultured 3T3-Ll cells, production of PGE2 was several fold higher in

preadipocytes compared to adipocytes, although it was still the main PG secreted during

all stages of cell development [113]. In order for PGE2 to act in an autocrine/paracrine

fashion, adipocytes must also express one or more of the EP receptors. Receptors

capable of binding PGE 1 were first demonstrated in rat adipocytes [121, 122].

Subsequent studies have demonstrated the expression of EP 1 , EP3 , and EP4 receptors in

OB 1771 preadipocytes as well as mouse precursor cells and mature adipocytes [123] .
Studies conducted on human adipocytes indicated the presence of two or more PGE2

binding sites with different affinities, but did not identify the receptors [13]. Taken

together, these studies indicate that PGE2 secreted by adipocytes is capable of acting in

an autocrine/paracrine manor to regulate adipocyte metabolism.
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D. PGE 2 Effects On Adipocytes

The primary and most immediate effect of PGE2 on adipocyte metabolism is the
inhibition of lipolysis through a reduction in cAMP [ 1 3, 1 24, 1 25], most likely mediated
through interaction with the EP3 receptor [ 126] . Further evidence indicated that the
major impact of PGE2 was on mature adipocytes versus preadipocytes, and that EP3
receptor mRNA was expressed only in mature adipocytes [ 1 23, 127] . Lipolysis has
displayed a biphasic response to PGE2 , with high levels stimulating this process [ 1 28],
although this study has been refuted on the grounds that the antilipolytic action of
adenosine was not controlled for in the earlier study [ 1 29]. Concurrent with a decrease in
lipolysis, PGE2 was also found to stimulate leptin release in primary cultures of mouse
adipose tissue. Both effects were partially reversed by the administration of NS-398, a
selective COX-2 inhibitor [ 1 30] . PGE2 may also play a role in modulating adipocyte
gene expression independent from its parent compound AA. Spot 1 4 is a nuclear protein
found primarily in lipogenic tissues, and has been shown to increase in a manner that
correlates with expression of lipogenic genes [ 1 3 1 ] . In 3T3-Ll cultures, AA was shown
to suppress S 14 and FAS mRNAs as has been demonstrated with other PUFAs, but the
activity on S 1 4 expression was reversed by the addition of a COX inhibitor. PGE2 at a
dose of 1 0 µM replicated this suppression via a pertussis toxin sensitive alteration in
cAMP levels [ 1 32]. Additional experiments looking at the effects of PGE 1 , PGE2 , and
PGE3 on PP AR isofonns found no effect for any of the PGE variants in activation of
these transcription factors [ 1 33]. It is clear that PGE2 can and does impact the metabolic
processes of lipolysis and lipogenesis in adipose tissue. What is not clear is the exact
mechanism. The presence of multiple isoforms of the EP receptor that are capable of
initiating similar, divergent or opposing signaling pathways makes it difficult to elucidate
the actions of PGE2 , and may indicate a host of actions depending on the physiological
conditions at the time. We therefore set out to clarify whether there is a specific role for
PGE2 in regulating FAS activity and expression.
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CHAPTER III
EXPERIMENTAL SECTION

PROSTAGLANDIN E2 SECRETION AND EFFECT ON MARKERS OF
LIPOGENESIS

I.

ABSTRACT
A dramatic rise in the incidence of obesity in the U.S. has accelerated the search

for interventions that may impact this epidemic. Prostaglandin E2 (PGE2 ) has been

shown to decrease lipolysis in adipocytes. Preliminary work conducted in our lab on
mice has also demonstrated a potential role for PGE2 in increasing the activity of a

lipogenic enzyme, fatty acid synthase (FAS). Taken together, these two actions would

lead to an increased accumulation of triglycerol in the adipocyte and increased adiposity.

From a dietary standpoint, one potential means of manipulating levels of PGE2 , and
possibly adipose tissue levels, is by increasing the consumption of preformed

eicosapentaenoic acid (EPA) in the diet. The purpose of this study was to determine

whether the concentration of PGE2, and lipogenesis as measured by FAS activity, could
be decreased by the addition of EPA or a selective COX-2 inhibitor. All studies were

conducted using cultures of differentiated 3T3-Ll adipocytes. Dose response studies

determined that 150 µM concentrations of AA and EPA resulted in approximately a 5fold difference in PGE2 secretion between the two treatments. Despite effectively

mediating the production of PGE2 (p<0.05), the addition of EPA resulted in no significant

decrease in FAS activity. Addition of celecoxib, a selective COX-2 inhibitor, also

significantly decreased PGE2 secretion {p<0.05) and did result in a significant decrease in

FAS activity (p<0.05). Unexpectedly, the combination of exogenous PGE2 and celecoxib
further decreased the FAS activity compared to PGE2 alone or untreated controls. In

conclusion, competitive inhibition of AA metabolism by EPA results in significantly
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decreased production of PGE2 when compared to AA treatment, but no significant

decrease in FAS activity. Selective inhibition of the COX-2 enzyme also significantly
decreases PGE2 production resulting in a decrease in FAS activity that is not reversed

with the addition of exogenous PGE2 , suggesting an additional mechanism that is not

mediated by COX-2.

II.

INTRODUCTION
The demonstration of endocrine roles for adipocytes has provided new insights

helping to explain the etiology of obesity. The secretion of prostaglandins such as PGE2

has been demonstrated in human and rodent adipocytes [16, 81, 113, 119]. The presence
of PGE2 receptors in these tissues as well [121-123] has led to research into a possible
autocrine or paracrine role for this AA metabolite. Several groups have shown that

endogenous PGE2 decreases lipolysis in cultured adipocytes and explants [13, 124, 125],

most likely acting through a G-inhibitory protein-coupled EP3 receptor [126], confirming

a paracrine/autocrine role of PGE2 in adipocytes. Several other roles for PGE2 in

adipocytes have been investigated and include regulation of leptin release and lipogenic

gene expression [11, 12].

Growth of adipose tissue is accomplished by increases in adipocyte size

(hypertrophy) and number (hyperplasia) [134], and is a hallmark of obesity. Increases in
adipocyte size are accompanied by an increase in stored lipids in the form of

triglycerides, which can be formed from circulating lipids or de novo lipogenesis [135].

To support de nova lipogenesis, glucose must be present to form the glycerol backbone of

the triglyceride, and enzymes of lipogenesis must be present to generate the fatty acids.

AA acid has been shown to stimulate glucose intake in adipocytes by increasing glucose

receptor levels in the cell membranes [136]. AA is also the preferential substrate for the

COX enzymes and the resultant production of PGs [10, 89]. In mature adipocytes, PGE2
is the primary PG produced from the COX pathway [113, 119]. Preliminary evidence
from our laboratory conducted on adipose tissue samples from ApcMinl+ mice [18]

indicated a possible role for PGE2 in increasing FAS activity, an indicator of lipogenesis.
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Further, adipose tissue from mice given the non-specific COX inhibitor piroxicam or

sulindac showed significantly decreased FAS activity versus controls, while the addition
of PGE2 receptor agonists partially and significantly reversed this effect [137]. Coupled

with the known effect of PGE2 in decreasing lipolysis, this effect on FAS activity would
lead to increased adipocyte triglyceride accumulation and hypertrophy.

Dietary EPA has demonstrated the capacity to impact adipocyte biological

functions via two distinct mechanisms. The first is via transcription factors that impact

the expression of genes involved in differentiation and lipogenesis. The second

mechanism is via direct competition with AA for incorporation into membrane

phospholipids and subsequent conversion to eicosanoids such as PGs via the COX

enzymes. The first mechanism has been extensively studied, while few studies have

addressed the second mechanism. The PGs (specifically PGE3) produced by the COX

action on EPA appear to have weaker action when compared to those produced by AA

(PGE2}, making displacement of AA by EPA a favorable outcome for attempts to control

excess adiposity.

Inhibition of AA metabolism to PGs can also be accomplished via

pharmacological intervention, and may provide a more direct mechanism to impact PGE2
actions. Compounds known to inhibit both isoforms of the COX enzymes, as well as

selective COX-2 inhibitors, have been shown to reduce PGE2 production in adipocytes

[2 1 -23, 81], and represent a second means to modulate PGE2 levels and investigate the

impact on lipogenesis.

The objective of this work is to investigate the impact of PGE 2 on fatty acid

synthesis via regulation of the FAS enzyme. We hypothesized that addition of EPA or

selective COX-2 inhibition would lead to a decrease in PGE2 production and subsequent
downregulation of markers of lipogenesis such as FAS enzyme activity (Fig. 6).

III.

MATERIALS AND METHODS

A. Animals

Male C57BL/6J ApcMinl+ mice (Jackson Labs, Bar Harbor, ME) were obtained at 38-45
22

EPA

Arachidonic Acid

Celecoxib
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Figure 6. Proposed Mechanism of Action for Decreased PGE 2 Secretion Via
EPA Competition

Gray arrows indicate autocrine function of PGE2/PGE3. Bold arrows indicate
known/proposed EPA mediated changes in PGE2 metabolism and action in adipocytes
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days of age. They were housed in a temperature-controlled room with 14 h periods of

light and 10 h periods of darkness and given free access to food and water. The health of
the animals was checked daily. Food was withheld overnight prior to sacrifice. All

animal procedures were approved by the University of Tennessee Animal Care and Use

Committee and were in accordance with the NIH Guide for the Care and Use of

Laboratory Animals (National Research Council, 1985)
B. Diets

Diets were composed of purified AIN93-G powder diet (Dyets, Inc., Bethlehem,

PA). Experimental diets containing NSAIDs were prepared daily by thoroughly mixing

piroxicam (Sigma, St. Louis, MO) with the control diet. Diets were stored at -20 ° C and

all animals were provided fresh food daily. Food consumption was monitored daily and
body weights were recorded weekly.
C. 3T3-Ll Cell Culture

Cells were purchased from American Type Culture Collection (ATCC, Rockville,

MD) and were grown in 100 mm dishes. Culture medium was composed of Dulbecco's
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (PBS)
and 1 % penicillin/streptomycin (P/S). Cells were plated on day 1 (-200,000 cells/! 00

mm dish) and grown for 3-4 days to confluence. At confluence, media was changed and
supplemented with 250 nM Dex, 0.5 mM Mix, and 10 nM insulin for 48 h to induce

adipocyte differentiation, after which cells were cultured with regular media.

Differentiation was considered complete at 5-7 days post-confluence (see Fig. 7 for time
line). Twenty-four hours prior to treatment, regular media was replaced with starvation
media consisting of DMEM, PIS, and 1% fatty acid free bovine serum albumin (BSA).
Treatment media consisted of starvation media+ 10 nM insulin and individual (FA or

inhibitor) treatments. All studies were conducted in differentiated cells (-80-95%).
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D. Experiment Design
Experiment 1 Male C57BL/6J ApcMinl+ mice were maintained on the AIN-93G

diet until 78-79 days of age at which time they were randomly assigned to one of four
groups { control, E-prostaglandin receptor agonist (EPR-A), piroxicam, or piroxicam +
EPR-A} . Groups receiving piroxicam (0.5 mg/mouse/day) were pair fed to ensure
equivalent dosing. The EPR-A, 16,16-dimethyl-PGE2 and 17-phenyl-trinor PGE 2
(Cayman Chemical, Ann Arbor, Ml), were administered as 10 µg each in sterile
phosphate buffered saline. The EPR-A or vehicle was administered in two daily IP
injections (0800, 1600) and once daily via gavage feeding (1200) to maximize exposure
to the GI tract over a 6 day period. Primary care and feeding of the mice was conducted
by Dr. Jay Whelan's lab in conjunction with his study on the role of PGE2 and colon
cancer [18] . The mice were sacrificed at 85-86 days of age by cervical dislocation and
epididymal adipose tissue was harvested, weighed, snap frozen in liquid nitrogen and
stored at -80° C. Liver weights were also obtained at the time of harvest.
Experiment 2 The goal of our dose response studies was to find a dose of EPA

that would significantly reduce PGE2 levels when compared to an equivalent
concentration of AA, while remaining physiologically relevant. 3T3-Ll cell cultures
were grown as above, and then treated with AA or EPA (Nu-Check Prep, Inc., Elysian,
MN) in 25, 50, 100, 200, and 500 µM doses. Two hours prior to treatment, fatty acids
were diluted to the appropriate concentration with dimethyl sulfoxide (DMSO), and then
added to treatment media and agitated in a shaking water bath at 37° C to facilitate FA
binding to BSA. Treatment time was 48 h for all doses. Two mL of media was removed
from each dish prior to cell harvest for analysis of PGE2 levels. Cell cultures were
harvested for cytosolic extracts.
Experiment 3 This control experiment was conducted to verify that changes in

PGE from adipocyte cultures treated with EPA were enzymatically driven. 3T3-Ll cell
cultures were treated with EPA (50 µM and 150 µM concentrations), the selective
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COX-2 inhibitor celecoxib (CI) (5 µM) (Pharmacia, St. Louis, MO), and EPA (1 50 µM)
+ CI (5 µM). In addition, culture media with EPA at 1 50 µM concentration was exposed
to cell culture conditions to facilitate lipid peroxidation. 48 hours following treatments,
two mL of media was removed from each dish to measure PGE2 levels and cells were
harvested for cytosolic extracts.
Experiment 4 The role of PGE2 in regulating the activity of the FAS enzyme

was investigated using 3T3-Ll cell cultures. Cell cultures were treated with vehicle
(DMSO), CI (1 µM), OA, EPA, AA, ( 1 50 µM each treatment) or AA + EPA (75 µM
each fatty acid). All fatty acids were added to treatment media and agitated in a shaking
water bath for 2 h at 37 °C prior to treatment of cells to facilitate binding to BSA.
Treatment time was 48 hours. Two mL of media was removed from each dish, and cell
cultures were harvested for cytosolic extracts or total RNA.
Experiment 5 To verify that PGE2 was responsible for the decrease in FAS

activity seen with selective COX-2 suppression, PGE2 was added back to mean levels
measured in the control groups of previous experiments. 3T3-Ll cell cultures were
treated with vehicle (DMSO), CI (1 µM), PGE2 (300 pM) (Cayman Chemical, Ann
Arbor, MI), and CI + PGE2 • 48 hours following treatment, two mL of media was
removed from each dish, and cells were harvested for cytosolic extracts or total RNA.
E. Methods
FAS assay The activity of FAS was determined in cytosolic extracts from mouse

adipose tissue and cell culture by measuring the rate of oxidation of NADPH [ 138].
Mouse adipose tissue collected from experiment 1 was homogenized on ice in 500 µL of
buffer (pH 7.4) containing 250 mM sucrose, 1 mM dithiothreitol, 1 mM EDTA, and 0. 1
mM phenylmethylsulfonyl fluoride (PMSF) for -- 30 seconds. Tissue homogenates were
centrifuged for lh (12,000 x g) at 4 °C. The supernatant was then removed for analysis
of FAS activity and protein concentration. Cell culture plates harvested for cytosolic
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extracts were washed twice in Hank's balanced salt solution, and then scraped using 350

µL of the buffer described above. Cell homogenates were sonicated on ice for 5 seconds

and centrifuged for l h (12,000 x g) at 4° C. The supernatant was then removed for
analysis of FAS activity and protein concentration.

Oxidized NADPH absorbs light at a wavelength of 340 nm. The absorption

change over a 5-minute time period was measured spectrophotometrically (Spectronic

Genesys 5) and was used to calculate the nmol ofNADPH oxidized per minute. These

values were corrected for protein concentration.

Protein assay Protein concentration was determined in cytosolic extracts by the

method of Bradford [139]. This assay utilizes the dye Coomassie blue (Bio-Rad,

Melville, NY), which has an affinity for basic and aromatic amino acids. The normally
red-brown dye absorbs light at 470 nm, but changes to a blue color when it binds to

amino acids and the absorption spectrum changes to 595 nm. Each sample was measured
in duplicate using 10 µL of sample and 200 µL of dye in a 96-well plate. After addition

of the dye, the samples were incubated for 5 minutes and read in a spectrophotometer at

590 nm. A standard curve was plotted using serial dilutions of a BSA standard of known

concentration and sample concentrations were extrapolated based on this standard curve.
PGE2 assay Cell culture PGE2 concentrations were determined using culture

media samples obtained immediately prior to cell harvest. PGE2 levels were measured by
enzyme immunoassay (EIA) using the Correlate-BIA PGEi Kit (Assay Designs, Ann

Arbor, MD according to the manufacturer's instructions. A standard curve was plotted

using serial dilutions of a known concentration of PGE 2 and sample concentrations were

extrapolated based on this standard curve.

Leptin assay Cell culture media samples were utilized in an attempt to measure

leptin levels. Initial attempts at measurement indicated very low leptin levels.

Centrifugal concentration was conducted using centricon® YM-3 filters (Millipore,

Billerica, MA) centrifuged at 7500 x g for 2 hours. Leptin measurement was attempted
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by two different methods. Radioimmunoassay (RIA) is a competitive protein-binding
assay, which utilizes a radiolabeled antigen (hormone) that competes with unlabeled

hormone in the sample for binding sites on an antibody. Measurement of radioactive

hormone bound to the antibody determines the amount of antigen present. This is

compared to a standard curve calculated from known concentrations of hormone to

determine the concentration of leptin. The RIA kit was purchased from Linco Research
(St. Charles, MO). Samples were 100 µL and were tested in duplicate. The second

method attempted, Enzyme Immuno Assay (EIA) utilizing the Mouse Leptin ELISA Kit
(Crystal Chem. Inc., Downers Grove, IL), utilized a more sensitive assay to detect the

presence of leptin. The assay was conducted using the manufacturer's instruction.
Sample volume was 5 µL with samples tested in duplicate. A standard curve was

constructed using samples of know concentration to determine leptin levels in culture
media.

Real time RT-PCR Real time RT-PCR utilizes fluorescent dyes to allow quick

and accurate quantification of mRNA, and is more sensitive than Northern blot methods
[140] . A probe is used that is designed to bind specifically to the target mRNA

sequence. This probe is labeled with 2 dyes: a fluorescent reporter dye on the 3' end and
a quencher dye on the 5 ' end. When no target sequence is bound, the quencher dye

resides in close proximity to the reporter dye and no fluorescence is detected. When a

target sequence is present, the probe will bind it and the distance between the two dyes is

extended to the point where fluorescence can now be detected. The intensity of

fluorescence thus increases directly with an increase in the number of target mRNA
sequences, which will reflect gene expression levels.

FAS mRNA expression was determined using this method. Cells harvested for

total RNA were scraped in 350 µL of Qiazol lysis reagent (Qiagen, Valencia, CA) and

sonicated on ice for 5 seconds. RNA was extracted using the RNeasy™ lipid tissue midi
kit (Qiagen) following the manufacturer's protocol. RNA was stored at -80° C for use in
real time RT-PCR and microarray analysis.
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The primers were ordered from Invitrogen (Carlsbad, CA). The sequence of the

forward primer is 5 'CCCAGAGGCTTGTGCTGACT 3'. The sequence of the reverse

primer is 5 'CGAATGTGCTTGGCTTGGT 3'. The probe was ordered from Biosearch

Technologies, Inc. (Novato, CA). The sequence of the probe is 5 ' (TET)CCGATCTG
GAATCCGCACCGG{TAMRA) 3 ' . TET is the quencher dye that inhibits the

fluorescence of the reporter dye when in close proximity. TAMRA is the reporter dye

and is measured at a wavelength of 580 nm. The SmartCycler SCl 000-1 and

SmartCycler software (Cepheid, Sunnyvale, CA) were programmed as indicated in Table
4.

Microarray analysis Microarray analysis is a relatively new technology used to

measure gene expression by determining the amount of mRNA present in a sample [ 141].

This is usually done for the gene or genes of interest by comparing the expression of the
gene(s) in a treatment group versus the expression of the same gene(s) in the control

group. The foundation of this technology is a glass slide or "chip" that can contain up to

450,000 spots composed of complimentary DNA (cDNA) sequences for specific genes.

mRNA samples from the control and 1 treatment group are converted to cDNA and

labeled with a separate dye (normally green for control and red for treatment). The

cDNA from each sample is placed on the same slide and incubated for 16-20 hours at

42° C. The slides are then washed and scanned by a laser that measures the intensity of

each spot.

Table 4. RT-PCR Programming Menu

Stage
1

2

3

Temperature
48 ° C

Time (seconds)

Number of Cycles

600

1

1,800

9s 0 c
9s 0 c

15

60° C

60
30

1
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Genes expressed by both the control and treatment will display approximately
equal intensity of both colors, while a gene expressed predominantly by the control or
treatment will display an intensity equal to that of the dye it was labeled with. The laser
generates separate files with the intensity of the red and green dye for each spot on the
chip. This data is then uploaded to software that combines the two files and displays the
intensity of each spot. This is then used to calculate gene expression for treatment
relative to the control.
Mouse cDNA microarray slides spotted with 15K mouse genes/expressed
sequence tags (EST) in duplicate were obtained from University Health Network
Microarray Center, Toronto, Canada. Total RNA from the control, CI, AA, EPA, AA +
EPA groups in experiment 3 were labeled with Cy3 (control) and Cy 5 (treatments) dUTP
dyes (Perkin Elmer, Shelton, CT). Hybridization was performed using the protocol
developed by The Institute of Genomic Research [142]. The slides were scanned with a
GSI 4000 scanner from GSI Lumonics (Perkin Elmer) and stored as TIFF files. The
scanned images were merged using ScanAlyze software (developed at Stanford
University) and uploaded into the Stanford Microarray Database (SMD) [143] installed at
the University of Tennessee for analysis. Intensity values for each spot were normalized
for background intensity and transformed logarithmically (base 2). Expression values are
given as a ratio of red/green (treatment/control) intensity, with inter and intra experiment
values for the same gene being averaged (control, CI, AA, EPA n = 4; AA + EPA n = 2)
to obtain reported gene expression levels. For the purpose of this thesis, microarray
analysis was only used to screen expression of a limited number of genes of interest.
These genes include FAS, glucose transporters 1 and 4 (GLUTl, GLUT4), SREBP,
prostaglandin E synthase (PGES), and two of the prostaglandin E receptor isoforms (EP2
and EP4).
Statistics Statistical analysis for all assays was conducted using SPSS (SPSS for

windows, version 12.0, SPSS Inc., Chicago, IL). Data were analyzed for homogeneity of
variance and for significant F ratios between treatment groups using one-way analysis of
variance (ANOVA). Post-hoc analysis was conducted using the Bonferroni (equal
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variance) or Dunnett's T3 (unequal variance) test when significant differences were

detected. All values are expressed as mean ± SEM. Values of p<0.05 were considered
statistically significant except where otherwise noted.

Statistical analysis for microarray was conducted using SAS (Cary, NC) on log

base 2 values. Outliers defined as observations >10 times the median absolute deviation
away from the median were discarded. Normalization was done with a loess smoothing

parameter of 0.3. Normalized and corrected data were analyzed with SAS mixed models

[144], including the random effect of array and fixed effect of dye. Differences in means

on the log scale are equivalent to ratios of gene expression, and the latter from SMD are
reported in the appendix.

IV.

RESULTS

Experiment 1. Effect of COX inhibition and EP receptor agonists in mouse adipose
tissue

This experiment was conducted as preliminary work to assist in defining a role for

COX specific products in modulating FAS activity. Non-specific inhibition of the COX

enzymes with piroxicam resulted in decreased FAS activity (p<0.02), while piroxicam +
EP receptor agonists resulted in significant partial restoration of FAS activity (p<0.02)
(Fig. 8). Treatment with EP receptor agonists alone also resulted in a significant

reduction in FAS activity when compared to control (p<0.02).

Experiment 2. Dose-Response effect of EPA and AA on PGE 2 secretion in 3T3-Ll
adipocytes

Consistent with studies that have shown the displacement of AA by EPA in tissue

phospholipids [5, 84, 85, 145], the levels of PGE2 were significantly lower when EPA

was added to the cell culture media compared to equivalent concentrations of AA (Fig.
9). As expected, addition of AA led to a powerful dose-dependant increase in PGE2

production. The two highest doses of EPA (200 µM and 500 µM) resulted in PGE2

levels that were significantly higher than control (p<0.03), although this is most likely
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attributed to PGE2 EIA assay cross- reactivity for PGE3 , which is reported by the

manufacturer to be 16.3%. FAS enzyme activity was analyzed for the various doses of

EPA and AA and displayed no significant changes when compared to control (Fig. 10)
except for AA 500 µM (p<0.03).

Experiment 3. Effect of EPA + CI treatment on measured PGE levels in cultured
3T3-Ll adipocytes

Addition of CI and EPA (150 µM) led to a significant reduction in measured PGE

activity (p<0.09) (Fig. 11). This data recapitulates our previous experiment and

demonstrates that the PGE formation is an enzymatic process, supporting the suggestion

that the increased levels measured in EPA treated cell cultures are a result of PGE3

formation. PGE levels for the other treatments used in this experiment were in line with

what has been seen in our previous experiments.

Experiment 4. Effect of selective COX-2 inhibition and EPA addition on PGE2
levels, FAS activity and FAS mRNA levels in 3T3-Ll adipocytes

PGE2 levels were effectively reduced compared to control by the addition of CI

(p<0.001). All fatty acid treatments resulted in measured increases in concentrations of

PGE2 compared to control, with concentrations increasing in the order of OA (p<0.05), <
EPA < AA + EPA < AA (all p<0.001) (Fig. 12). Consistent with the decrease in PGE2

levels, FAS enzyme activity was significantly decreased by treatment with CI (p<0.05).
Treatment with EPA and AA resulted in trends similar to those seen from the dose

response study but did not reach statistical significance (Fig. 13). Attempts to measure

leptin levels in culture media consistently resulted in concentrations just at or below the
minimum sensitivity of both methods attempted. After several trials that included

different cultures and culture conditions, we concluded that leptin levels were too low to

be used as a marker for our studies and therefore did not include measurements of media

leptin levels in this thesis. Expression of FAS mRNA analyzed by real time RT-PCR and

microarray showed a significantly decreased expression for all FA treatments versus

control (p<0.05) (Fig. 14). The level of reduction of FAS mRNA for the FA treatments
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correlates well with the degree of unsaturation and chain length and may therefore reflect
a non-specific PUFA effect [70, 72].
Experiment 5. Effect of exogenously added PGE 2 on selective COX-2 inhibition of
endogenous PGE 2 secretion, FAS activity, and FAS mRNA levels in 3T3-Ll
adipocytes.

As demonstrated in our previous experiments, addition of CI resulted in a
significant decrease in PGE2 production (p<0.04). Addition of PGE2 to cultures with CI
treated cells restored PGE2 levels and resulted in significantly higher levels versus CI
treatment alone and versus control (p<0.02) (Fig. 1 5). Addition of PGE2 to cultures
without CI resulted in the expected significant increase over control levels (p<0.02). The
level of PGE2 added was based on the mean of previously measured levels of PGE2
secreted by 3T3-Ll control groups (300 pM).
Analysis of FAS enzyme activity and mRNA expression, however, produced
unexpected results. Treatment with CI resulted in a consistent decrease in enzyme
activity that did not reach statistical significance as in the previous experiments.
Treatment with CI plus exogenous PGE2 actually resulted in a significant decrease in
FAS activity (p<0.03) instead of reversing it (Fig. 1 6). Addition of PGE2 alone, in the
absence of CI, resulted in no change in FAS activity. Real time RT-PCR analysis of FAS
mRNA expression indicated that CI treatment had no significant effect in this
experiment. In contrast, and in agreement with the combined effects of CI and PGE2 on
FAS activity, FAS mRNA expression was also decreased by the combined treatment vs.
all other individual treatments (Fig. 1 7).

V.

Discussion
Despite the vast amount of research that has been conducted on PGE2, much still

remains to be learned about its impact on adipocyte metabolism. It is well documented
that PGE2 can and does decrease lipolysis in adipocytes [ 1 3, 1 24- 126], but we questioned
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whether this action was associated with other actions that could be considered anti

lipolytic or lipogenic. Data from in vivo studies performed in tissues harvested from the

ApcMinl+ mice clearly indicated that inhibition of the COX enzymes by piroxicam,

sulindac, or aspirin (unpublished data) led to decreased FAS activity. Reversal of this

inhibition by EP receptor agonists pointed to a lipogenic role that might be coupled with

the decrease in lipolysis already known to occur. Several factors inherent in this study

required us to continue this investigation in adipocyte models to further delineate possible

direct actions of PGE2 in adipocytes. The most prominent shortcoming of these earlier
studies was an inherent defect in the Ape gene of this CRC mouse model [146],

potentially contributing to several metabolic inconsistencies that might impact adipocyte
metabolism. For example, due to their condition, fat mass accretion is typically below

that of age-matched controls. These mice also exhibit elevated PGE2 levels associated
with high numbers of intestinal tumors [18]. The results found in these studies would

therefore require verification using other wild type mice models more suited for the study

of adipocyte metabolism in vivo; or use of adipocyte cell models in culture to determine

direct cellular and molecular actions of PGE2 in these cells.

3T3-Ll adipocytes were chosen as a model to further investigate the direct actions

and role for PGE2 in modulating FAS activity. Two separate mechanisms were selected
to attempt modulation of PGE2 levels secreted by the adipocytes. Pharmacological

intervention utilized celecoxib, a selective COX-2 inhibitor, to inhibit metabolism of AA

to PGH2 , which we proposed would lead to a decrease in PGE2. EPA was also utilized to
competitively inhibit AA metabolism, representing a dietary intervention that we also
proposed would decrease adipocyte PGE2 production.

Dose response studies demonstrated an approximately linear increase in measured

PGE2 levels for AA and EPA, with a highly significant difference (p<0.001) between the
two treatments at the 200 µM concentration. Very little information exists in the

literature regarding physiological levels of EPA. Liebich et al measured free EPA levels

in plasma using gas chromatography and found them to be approximately 6.6 µM [147].
Studies conducted on postmenopausal women fed fish oil found the EPA levels of all

plasma lipids was 750 µM, and that LDL phospholipids and cholesterol esters contained
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57.5 nmoVmg protein [84, 145]. Given the approximate ten-fold reduction in measured
PGE2 levels between EPA and AA at the 1 00 to 200 µM concentrations, 1 50 µM was
chosen for our dosage. Consistent with the findings of other studies [5, 1 6] , we
demonstrated the ability to manipulate secreted PGE2 by using EPA to compete with AA
for incorporation into membrane phospholipids and subsequent PG production.
PGE2 levels in the CI treatment group were significantly lower than controls,
providing a clear-cut reduction in PGE2 production. Although the CI is a selective
COX-2 inhibitor, it is uncertain as to the specific mechanism of PGE2 reduction. Most
published evidence indicates that COX-2 is not expressed at physiologically relevant
levels in mature adipocytes under normal conditions [2 1 , 82]. One possible explanation
for the activity of the CI may be that the IC50 of this compound for COX-1 is reported as
1 .2 µM [ 1 48], thus putting our 1 µM concentration high enough to inhibit some COX-1
function.
To determine the impact of manipulating PGE2 levels, we used FAS enzyme
activity as a marker of adipocyte lipogenesis. We report a significant decrease in FAS
activity with the CI treatment. Lu et al, using aspirin for non-specific COX inhibition,
have also reported similar effects by measuring accumulation of triacylglycerols in
adipocytes [2 1 ], although the duration of their treatment was 6 days making direct
comparison impossible.
The overall comparison of PGE2 levels for the AA, EPA, and AA + EPA
treatment groups correlated well with previously published data measuring tissue
concentrations of these fatty acids in mice fed diets supplemented with them [5], although
the end points measured and experimental models were different [5, 85, 149] . This
served to help verify that our method of incubating the free fatty acid treatments with the
fatty acid free BSA did in fact result in the albumin binding the fatty acids, and that the
fatty acids were being incorporated into the cell membrane phospholipids.
Although the measured PGE2 levels were significantly lower in EPA
treatment versus AA treatment, they were still significantly higher than control levels.
This finding may be partially accounted for by considering PGE3 cross-reactivity, but
because the actual media content of PGE3 was not measured it is impossible to know the
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ratio of the PGE isoforms. Complicating this issue further is the fact that very little is

known concerning the actions of PGE3 . Studies in NIH 3T3 fibroblasts found that PGE3

activated the same signaling pathways as PGE2, but with much less efficiency [16]. This
would imply that high levels of PGE3 may duplicate the actions of PGE2 , suggesting

there would be a point of diminishing returns with EPA supplementation. It is also

possible that PGE3 may bind EP receptors with affinities that differ significantly from

PGE2 , whereby the type and number of receptors in adipocytes would also influence the
impact of EPA supplementation. An additional study was undertaken to verify that the

measured changes in PGE formation in EPA treated cells was mediated via an enzymatic
process. This data recapitulates our previous experiment and demonstrates that the PGE
formation is an enzymatic process, and since no exogenous AA was added to the cells

these data collectively support the suggestion that production of PGE3 is responsible for

the increases seen in PGE production.

It is important to note that measuring enzyme activity only gives a picture of the

quantity of enzyme present at the time of harvest and does not reflect regulation at other

levels such as transcription, translation, and protein half-life that impact the quantity of

enzyme present and therefore the product formed (in this case FAs and subsequently

triacylglycerols). Since FAS is well documented to be primarily regulated -whether

nutritionally or hormonally- at the level of gene transcription [150-152], we examined the
impact of our treatments on the genetic regulation of the FAS enzyme using real time

RT-PCR and microarray analysis. The use of these small- and large-scale gene analysis
methods, respectively, relays information regarding the expression of FAS mRNA or

other genes of interest for a given treatment relative to the control. Both RT-PCR and

microarray analysis indicated a clear reduction in FAS mRNA for all treatments versus

the control. The effect of fatty acid treatment was substantial, with the reduction

correlating well with degree of unsaturation and chain length as previously reported for

hepatic FAS and other lipogenic gene regulation [153, 154]. This effect also very closely
resembles results from Deng et al showing that degree of unsaturation correlated highly
with suppression of the SREBP-l c promoter [72].
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Treatment with EPA and AA led to significantly increased PGE levels versus

control, yet both treatments suppressed FAS mRNA expression compared to control

values. Treatment with CI led to reductions in PGE production, yet treatment with CI in

experiment 4 also led to reduced FAS mRNA when compared to control. These data

demonstrating opposing changes in PGE levels with similar reductions in FAS mRNA
seem to indicate nuclear regulation as playing a key role in these changes for AA and

EPA treatment independent of PGE levels. Since mRNA stability was not measured in

these experiments, it is possible that increased stability was responsible for the

discrepancy created by decreased FAS mRNA expression and unchanged FAS activity

for PUFA treatments. It is also possible this discrepancy is due to a longer half-life of the

FAS protein such that we were unable to detect changes in enzyme activity within our
treatment times (24-48 hours).

Indeed, previous studies have shown changes in FAS

mRNA half life depend on cell culture treatment and state of differentiation [ 1 52, 1 55].
When exogenous PGE2 was added to cells treated with and without CI, we

obtained very surprising results. Although PGE2 levels in media were significantly

higher than controls, FAS activity with PGE2 added to CI was significantly lower than

controls. This was in direct opposition to what was expected, and what has been shown
by other experiments [2 1 ]. In addition to the duration of treatment, another possible
explanation for this result may be linked to leptin secretion. PGE2 was shown to

stimulate leptin secretion in mouse adipose tissue in primary culture [ 1 30], and elevated

leptin levels decrease lipogenesis [ 1 56] and specifically impact FAS by decreasing gene

expression [ 1 57, 1 58]. It is unfortunate we were not able to measure cell culture leptin

levels, as this would have enabled us to determine whether the exogenous PGE2 did result

in increased leptin levels. A second possible mechanism involves the antithetic actions of
the EP receptors. Long et al investigated the role of COX mediated products of AA

metabolism on regulation of glucose transporter 4 (GLUT 4) regulation. They found that

a 50-fold increase in endogenous PGE2 or exposure to 1 0 µM exogenous PGE2 resulted

in an increase in cAMP concentrations, consistent with activation of the EP2/EP4 receptor
[ 1 59]. Additionally, studies using the specific COX-2 inhibitor NS-398 on cortical

collecting duct cells found that NS-398 treatment increased EP3 and EP4 receptor
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expression 3-fold [160]. Although the concentration of exogenous PGE2 added in our
treatments was much lower, our preliminary microarray data indicated that celecoxib also
influenced the expression ofEP receptors (specifically EP4) and may have resulted in
findings different from other experiments utilizing aspirin or other non-specific COX
inhibitors. An increase in EP4 receptors and the resulting increase in cAMP would
activate a pathway that would oppose the decrease in cAMP responsible for the PGE2
mediated decrease in lipolysis. If our hypothesis was correct that this pathway was also
responsible for an increase in FAS activity, then activating the opposing pathway should
lead to a decrease in FAS activity. Further work with EP receptor concentration and
mechanism of action is necessary to delineate the impact of each receptor and how they
function in a mixed company.
Measurement ofFAS mRNA expression by RT-PCR showed a reduced
expression with the CI + PGE2 treatment (as seen with the enzyme activity), and
increased expression with treatment by CI alone when compared to control. This result
also seems to indicate an action of the CI that is further impacted by the addition of
exogenous PGE2 • This may be tied to EP receptor expression and signaling or may be a
separate and additional action of the CI acting through regulation of transcription.
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CHAPTER IV
CONCLUSIONS AND FUTURE DIRECTIONS
Our studies demonstrated the ability to pharmacologically decrease production of
PGE2 using the selective COX-2 inhibitor celecoxib, which resulted in a significant
reduction in measured FAS activity. The use of EPA was also shown to decrease the
production of PGE when compared to AA treatment, but not when compared to control.
The PG products resulting from COX action on EPA did p.ot result in a significant
decrease in FAS enzyme activity, most likely due to higher levels of the two PGE
isoforms compared to control. Attempts to restore CI reduced FAS activity with
exogenous PGE2 resulted in further suppression of activity, contrary to what was
expected. This suggests a possible alternate pathway in the action of the CI treatment
independent of COX suppression.
FAS mRNA expression was decreased by FA treatment in a manner similar to
the PUFA effects seen in liver tissue. Given that SREBP l c, an insulin responsive
transcription factor, mediates PUFA regulation of hepatic lipogenic genes it is possible
that PUFA regulation of adipocyte metabolism modulates insulin sensitivity. Indeed, in
the absence of insulin, our cells expressed significantly higher PGE2 levels than in the
presence of insulin.

Further experimentation is required to determine the mechanism of action of
celecoxib and PGE2 in adipose tissue, and to resolve the seeming inconsistency in the
role of PGE2 in modulating FAS enzyme activity and mRNA content. While we were
able to demonstrate regulation of PGE2 levels in adipocytes by n-3 PUFA, we were
limited by the small responsiveness of the FAS model, especially at the enzyme level.
Lack of simultaneous analysis of several markers of adipocyte metabolism is a weakness
in our experiments and should be included in future studies. Finally, additional data on .
the receptor affinities and actions of PGE3 , although difficult to approach at this time
given the lack of data in this area, is necessary in order to understand the mechanism
mediating EPA and PGE3 effects on lipid metabolism.
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We have demonstrated in vitro using a well-accepted model of adipocyte

metabolism that EPA does reduce tissue AA levels in adipocytes and results in a

significant reduction in the PGE 2 produced. In addition, pharmacological intervention

via inhibition of the COX pathway also resulted in significant inhibition of PGE 2

production. Although a direct impact on the activity of FAS was not consistently

demonstrated, a reduction in PGE 2 levels would still result in less inhibition of lipolysis.

Less inhibition of lipolysis, coupled with the other known gene-regulated actions of EPA
and other polyunsaturated fatty acids, would still favorably impact adipose tissue levels

and result in decreased adiposity. Given the widespread use of celecoxib as an arthritis

medication, and the problem of lack of mobility for many who suffer from arthritis, the

implication of increased lipolysis and a potential for decreased lipogenesis may prove a
benefit for those who take it.

This study also brings to light the need for studies on the function and impact of

PGE 3 in adipocytes to determine if it does in fact elicit the same responses as PGE 2. If

this is the case, then it may indicate a point of diminishing benefit and the need to specify
a consumption range instead of recommending minimum consumption levels.

Understanding the mechanisms involved with EPA metabolism takes on further

importance with the recent FDA move to allow qualified health claims for omega-3 fatty

acids [161], as this will most certainly bring more attention to these fatty acids and
increase their consumption even further.
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The recent development of microarray analysis has given researchers a tool with
almost unlimited potential to identify and understand the complex nutrient gene
interactions that impact obesity. Although microarray analysis was not part of the
original proposal for this thesis, the opportunity to use this incredible tool was too good
to pass up. Microarray analysis was conducted following the procedures for experiment
#3 on two separate occasions. Since each slide had duplicate spots, this gave a total of 4
values for each gene tested, with the exception of the AA + EPA treatment group which
only had two values due to insufficient RNA from the second trial. Statistics were run on
all genes for each treatment, but due to the low number of values (n = 4), no statistical
significance was found on any of our genes of interest. Despite these results, the
expression of specific genes in the treatment group relative to the controls provided an
interesting snapshot of the impact of a given treatment. The following chart gives the
relative expression of treatment versus control for several genes of interest to this work.
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Table Al . Microarray Results for Selected Genes.

Gene

GLUT l

GLUT 4
SREBP

Treatment

CI

AA
1.11

1.51*

1.20

1.80*

0.84

EPA

1.58

1.32

0.66
2.03

0.19*

1.98

3.30*

0.47*

0.14*

EP2

0.75

1.83

2.10

EP4

1.20

1.54

3.30

2.21*

1.20*

0.41*
0.92

1.14*

2.80

FAS

PGES

AA+ EPA

0.24*
1.41*

Values reported are means for 4 spots except for * which indicates mean for 2 spots.
Values indicate relative expression of each gene versus control, where 1.00 would
indicate expression identical to control.

GLUT = glucose transporter

SREBP = Sterol regulatory element binding protein

FAS = Fatty acid synthase

PGES = Prostaglandin E synthase

EP = Prostaglandin E receptor

71

VITA
Patrick Allen Wortman was born in Wichita, Kansas on March 7, 1 964. He
received an Honorable Discharge from the U.S. Navy after 9 years of service. He
received an Associate in Arts from Lake-Sumter Community College in Leesburg,
Florida in 1 998, and then transferred to The University of Tennessee to complete his
undergraduate work in nutrition. Graduate study in the field of nutrition was also
completed at The University of Tennessee in December 2004.

72

590 1 111 1 �491
14/16/85

tm

